Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	The Angels Initiative Stroke prevention

Lung Cancer

Free Subscription Articles published in J Nucl Med Retrieve available abstracts of 17 articles: HTML format

Single Articles

December 2022
1. SHIYAM SUNDAR LK, Hacker M, Beyer T
   Whole-body PET imaging: A catalyst for whole-person research?
   J Nucl Med. 2022 Dec 2:jnumed.122.264555. doi: 10.2967/jnumed.122.264555.
   PubMed     Abstract available
   
   
   August 2022
2. BOULEAU A, Nozach H, Dubois S, Kereselidze D, et al
   Optimizing Immuno-PET Imaging of Tumor PD-L1 Expression: Pharmacokinetic, Biodistribution, and Dosimetric Comparisons of (89)Zr-Labeled Anti-PD-L1 Antibody Formats.
   J Nucl Med. 2022;63:1259-1265.
   PubMed     Abstract available
   
   
   June 2022
3. STERBIS E, Liang R, Trivedi P, Kwak J, et al
   Lack of adherence to guideline-based imaging prior to subsequent radiation in patients with non-small cell lung cancer: Impact on patient outcomes.
   J Nucl Med. 2022 Jun 9. pii: jnumed.122.264131. doi: 10.2967/jnumed.122.264131.
   PubMed     Abstract available
   
   
   April 2022
4. KUNIHIRO AG, Sarrett SM, Lastwika KJ, Solan JL, et al
   CD133 as a Biomarker for an Autoantibody-to-ImmunoPET Paradigm for the Early Detection of Small Cell Lung Cancer.
   J Nucl Med. 2022 Apr 28. pii: jnumed.121.263511. doi: 10.2967/jnumed.121.263511.
   PubMed     Abstract available
   
   
   March 2022
5. BUCK AK, Haug A, Dreher N, Lambertini A, et al
   Imaging of C-X-C Motif Chemokine Receptor 4 Expression in 690 Patients with Solid or Hematologic Neoplasms using (68)Ga-PentixaFor PET.
   J Nucl Med. 2022 Mar 3. pii: jnumed.121.263693. doi: 10.2967/jnumed.121.263693.
   PubMed     Abstract available
   
   
   
6. YUSUFALY TI, Mell LK
   Reply: Adding Nontumor Radiomic Features to the Prognostic Model Is Bothersome but Useful.
   J Nucl Med. 2022;63:495.
   PubMed    
   
   
   
7. ZHANG L, Zhang B
   Adding Nontumor Radiomic Features to the Prognostic Model Is Bothersome but Useful.
   J Nucl Med. 2022;63:494-495.
   PubMed    
   
   
   February 2022
8. ZIDAN L, Iravani A, Oleinikov K, Ben-Haim S, et al
   Efficacy and Safety of (177)Lu-DOTATATE in Lung Neuroendocrine Tumors: A Bicenter study.
   J Nucl Med. 2022;63:218-225.
   PubMed     Abstract available
   
   
   December 2021
9. KOLINGER GD, Vallez Garcia D, Kramer GM, Frings V, et al
   Effects of tracer uptake time in non-small cell lung cancer (18)F-FDG PET radiomics.
   J Nucl Med. 2021 Dec 21. pii: jnumed.121.262660. doi: 10.2967/jnumed.121.262660.
   PubMed     Abstract available
   
   
   August 2021
10. FARWELL MD, Gamache RF, Babazada H, Hellmann MD, et al
    CD8-targeted PET Imaging of Tumor Infiltrating T cells in Patients with Cancer: A Phase I First-in-Human Study of (89)Zr-Df-IAB22M2C, a Radiolabeled anti-CD8 Minibody.
    J Nucl Med. 2021 Aug 19. pii: jnumed.121.262485. doi: 10.2967/jnumed.121.262485.
    PubMed     Abstract available
    
    
    
11. SMIT J, Borm FJ, Niemeijer AN, Huisman MC, et al
    PD-L1 PET/CT imaging with radiolabeled durvalumab in patients with advanced stage non-small cell lung cancer.
    J Nucl Med. 2021 Aug 12. pii: jnumed.121.262473. doi: 10.2967/jnumed.121.262473.
    PubMed     Abstract available
    
    
    July 2021
12. ZHOU X, Jiang J, Yang X, Liu T, et al
    First-in-human evaluation of a PD-L1-binding peptide radiotracer in non-small cell lung cancer patients with PET.
    J Nucl Med. 2021 Jul 29. pii: jnumed.121.262045. doi: 10.2967/jnumed.121.262045.
    PubMed     Abstract available
    
    
    
13. ROHRICH M, Leitz D, Glatting FM, Wefers AK, et al
    Fibroblast Activation Protein specific PET/CT imaging in fibrotic interstitial lung diseases and lung cancer: a translational exploratory study.
    J Nucl Med. 2021 Jul 16. pii: jnumed.121.261925. doi: 10.2967/jnumed.121.261925.
    PubMed     Abstract available
    
    
    
14. NIEMEIJER AN, Oprea Lager DE, Huisman MC, Hoekstra OS, et al
    First-in-human study of (89)Zr-pembrolizumab PET/CT in patients with advanced stage non-small-cell lung cancer.
    J Nucl Med. 2021 Jul 16. pii: jnumed.121.261926. doi: 10.2967/jnumed.121.261926.
    PubMed     Abstract available
    
    
    May 2021
15. GUBERINA M, Poettgen C, Metzenmacher M, Wiesweg M, et al
    PROGNOSTIC VALUE OF POST-INDUCTION CHEMOTHERAPY VOLUMETRIC PET/CT PARAMETERS FOR STAGE IIIA/B NON-SMALL CELL LUNG CANCER PATIENTS RECEIVING DEFINITIVE CHEMORADIOTHERAPY.
    J Nucl Med. 2021 May 20. pii: jnumed.120.260646. doi: 10.2967/jnumed.120.260646.
    PubMed     Abstract available
    
    
    January 2021
16. LAFFON E, Marthan R
    Distribution Volume of (18)F-BMS-986192 in NSCLC Patients.
    J Nucl Med. 2021;62:144.
    PubMed    
    
    
    June 2020
17. FERDINANDUS J, Barbato F, Chodyla M, Fendler WP, et al
    Volumetric PET response assessment outperforms conventional criteria in patients receiving high-dose pembrolizumab for malignant mesothelioma.
    J Nucl Med. 2020 Jun 12. pii: jnumed.120.245803. doi: 10.2967/jnumed.120.245803.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: